- Home
- ADPT vs GGN Comparison
ADPT vs GGN Comparison
Compare ADPT & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- GGN
- Stock Information
- Founded
- ADPT 2009
- GGN 2005
- Country
- ADPT United States
- GGN United States
- Employees
- ADPT 709
- GGN N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- GGN Finance/Investors Services
- Sector
- ADPT Health Care
- GGN Finance
- Exchange
- ADPT Nasdaq
- GGN Nasdaq
- Market Cap
- ADPT 749.7M
- GGN 663.2M
- IPO Year
- ADPT 2019
- GGN N/A
- Fundamental
- Price
- ADPT $5.08
- GGN $4.04
- Analyst Decision
- ADPT Buy
- GGN
- Analyst Count
- ADPT 4
- GGN 0
- Target Price
- ADPT $6.50
- GGN N/A
- AVG Volume (30 Days)
- ADPT 1.1M
- GGN 397.4K
- Earning Date
- ADPT 11-07-2024
- GGN 01-01-0001
- Dividend Yield
- ADPT N/A
- GGN 10.26%
- EPS Growth
- ADPT N/A
- GGN N/A
- EPS
- ADPT N/A
- GGN N/A
- Revenue
- ADPT $177,282,000.00
- GGN N/A
- Revenue This Year
- ADPT $3.82
- GGN N/A
- Revenue Next Year
- ADPT $20.38
- GGN N/A
- P/E Ratio
- ADPT N/A
- GGN N/A
- Revenue Growth
- ADPT N/A
- GGN N/A
- 52 Week Low
- ADPT $2.28
- GGN $3.51
- 52 Week High
- ADPT $6.70
- GGN $3.91
- Technical
- Relative Strength Index (RSI)
- ADPT 47.04
- GGN 24.00
- Support Level
- ADPT $5.09
- GGN $4.02
- Resistance Level
- ADPT $6.70
- GGN $4.38
- Average True Range (ATR)
- ADPT 0.46
- GGN 0.06
- MACD
- ADPT 0.00
- GGN -0.04
- Stochastic Oscillator
- ADPT 24.48
- GGN 5.46
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About GGN GAMCO Global Gold Natural Resources & Income Trust
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option strategy of writing (selling) covered call options on equity securities in its portfolio.